Last reviewed · How we verify
MSP3 vaccine
MSP3 vaccine is a Biologic drug developed by African Malaria Network Trust. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MSP3 vaccine |
|---|---|
| Sponsor | African Malaria Network Trust |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MSP3-CRM-Vac4All/ Alhydrogel® Vaccine (PHASE1, PHASE2)
- MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine (PHASE1)
- Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa (PHASE2)
- Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years (PHASE1)
- A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (PHASE1)
- Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine (PHASE2)
- Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine (PHASE1)
- Phase Ib Trial of MSP3 LSP in Children in Tanzania (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSP3 vaccine CI brief — competitive landscape report
- MSP3 vaccine updates RSS · CI watch RSS
- African Malaria Network Trust portfolio CI
Frequently asked questions about MSP3 vaccine
What is MSP3 vaccine?
Who makes MSP3 vaccine?
What development phase is MSP3 vaccine in?
Related
- Manufacturer: African Malaria Network Trust — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing